Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 181

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz, Angela Dispenzieri, Shaji K Kumar, Anita D'Souza, Anannya Patwari, Andrew J Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan Schönland, Suzanne Lentzsch, Eli Muchtar

Blood blood.2024025899.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Contemporary Multiple Myeloma Treatment Patterns Among HCPs and Concordance with Expert Recommendations: Analysis of an Interactive Online Decision Support Tool

Kelly G Brandt, Kristen Rosenthal, Shaji Kunnathu Kumar, Suzanne Lentzsch, Sagar Lonial, Saad Z Usmani, Timothy A. Quill, Joseph R. Mikhael

Blood (2023) 142 (Supplement 1): 7284.

https://doi.org/10.1182/blood-2023-180957

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Daniel T Peters, Jacob Amburn, Sascha Tuchman, Eben I Lichtman, Christopher Edward Jensen, Koyal Jain, Suzanne Lentzsch, Rajshekhar Chakraborty, Divaya Bhutani, Samuel M Rubinstein

Blood (2023) 142 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2023-189341

Published: 2023

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

Journal Articles

Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African Population

Blood (2023) 142 (Supplement 1): 4767.

https://doi.org/10.1182/blood-2023-172435

Published: 2023

Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2023-180761

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Blood (2023) 142 (Supplement 1): 4784.

https://doi.org/10.1182/blood-2023-188115

Published: 2023

Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Blood (2023) 142 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2023-181905

Published: 2023

Journal Articles

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Ran Reshef, Mathew S Maurer, Jai Radhakrishnan, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2023-187214

Published: 2023

Journal Articles

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Jing Fu, Shirong Li, Guifen Liu, Huihui MA, Christophe Marcireau, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6618.

https://doi.org/10.1182/blood-2023-190740

Published: 2023

Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2023) 142 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2023-174908

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Michael Sang Hughes, Siyang Leng, Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Shahzad Raza, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6576.

https://doi.org/10.1182/blood-2023-182842

Published: 2023

Journal Articles

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Mateo Mejia Saldarriaga, Caitlin Unkenholz, Joshua A Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2023) 142 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2023-187832

Published: 2023

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling

Jing Fu, Shirong Li, Huihui MA, Lewis M Brown, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2023-189820

Published: 2023

Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood (2022) 140 (Supplement 1): 10140–10141.

https://doi.org/10.1182/blood-2022-159969

Published: 2022

Journal Articles

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Stephanie Scalia, Denis Toskic, Ping Zhou, Mahesh M Mansukhani, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10120–10121.

https://doi.org/10.1182/blood-2022-162352

Published: 2022

Journal Articles

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Morie A. Gertz, Rafat Abonour, Sarah N. Gibbs, Muriel Finkel, Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany P. Quock, Cara A. Rosenbaum, Michael Rosenzweig, Surbhi Sidana, Sascha A. Tuchman, Ronald Witteles, Irina Yermilov, Michael S. Broder

Blood (2022) 140 (Supplement 1): 13129–13131.

https://doi.org/10.1182/blood-2022-156832

Published: 2022

NARROW

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Contemporary Multiple Myeloma Treatment Patterns Among HCPs and Concordance with Expert Recommendations: Analysis of an Interactive Online Decision Support Tool

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African Population

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only